L. Eschen
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by L. Eschen.
Radiation Oncology | 2015
Vivek Verma; Jingxia Liu; L. Eschen; Jonathan Danieley; C.R. Spencer; James S. Lewis; Jason A. Diaz; Jay F. Piccirillo; Douglas Adkins; Brian Nussenbaum; Wade L. Thorstad
BackgroundThis study explores variables associated with poor prognosis in postoperative p16 positive oropharyngeal squamous cell carcinoma (OPSCC) patients undergoing adjuvant radiotherapy or chemoradiotherapy. Specifically, analysis was done related to timing of feeding tube insertion relative to radiotherapy.MethodsFrom 1997–2009, of 376 consecutive patients with OPSCC, 220 received adjuvant IMRT, and 97 were p16 positive and eligible. Of these, 23 had feeding tube placement before IMRT (B-FT), 32 during/after IMRT (DA-FT), and 42 had no feeding tube (NO-FT). Feeding tubes were not placed prophylactically. These three groups were analyzed for differential tumor, patient, treatment, and feeding tube characteristics, as well as differences in overall survival (OS), disease free survival (DFS), and distant metastasis free survival (DMFS).ResultsPre-RT FT insertion was associated with higher tumor size and depth, T (but not N) and overall stage, comorbidities, presence of chemotherapy, and less use of transoral laser microsurgery/transoral bovie. Additionally, time from surgery to IMRT completion was also statistically longer in the B-FT group. The feeding tube was permanent in 52% of patients in the B-FT group versus 16% in the DA-FT group (p = 0.0075). The 5-year OS for the NO-FT, DA-FT, and B-FT groups was 90%, 86%, and 50%, respectively. The 5-year DFS for the NO-FT, DA-FT, and B-FT groups was 87.6%, 83.6%, and 42.7%, respectively. Multivariate analysis showed that for OS and DFS, feeding tube placement timing and smoking history were statistically significant.ConclusionDue to the poor prognosis of early FT insertion, the presence of FTs at time of radiotherapy consultation can be used as an alternate marker to identify a subset of p16 positive OPSCC patients that have a poor prognosis.
Clinical and Translational Radiation Oncology | 2018
Jung Hun Oh; A. Apte; Mackenzie Daly; Douglas Adkins; Jason T. Rich; Peter Oppelt; Pawel T. Dyk; D. Mullen; L. Eschen; R.I. Chin; Brian Nussenbaum; Bruce H. Haughey; Wade L. Thorstad; Joseph O. Deasy
Background and purpose Acute pain during weekly radiotherapy (RT) to the head and neck is not well characterized. We studied dose-volume metrics and clinical variables that are plausibly associated with throat or esophageal pain as measured with a weekly questionnaire during RT. Materials and methods We prospectively collected weekly patient-reported outcomes from 122 head and neck cancer patients during RT. The pain score for each question consisted of a four-level scale: none (0), mild (1), moderate (2), and severe (3). Univariate and multivariate ordinal logistic regression analyses were performed to investigate associations between both esophageal and throat pain and clinical as well as dosimetric variables. Results In multivariate analysis, age was significantly associated with both types of pain, leading to odds ratio (OR) = 0.95 (p = 0.008) and OR = 0.95 (p = 0.007) for esophageal and throat pain, respectively. For throat pain, sex (OR = 4.12; p = 0.010), with females at higher risk, and fractional organ at risk (OAR) mean dose (OR = 3.30; p = 0.014) were significantly associated with throat pain. Conclusions A fractional OAR mean dose of 1.1 Gy seems a reasonable cutoff for separating no or mild pain from moderate to severe esophageal and throat pain. Younger patients who received RT experienced more esophageal and throat pain. Females experienced more throat pain, but not esophageal pain.
Medical Physics | 2014
Jung Hun Oh; A. Apte; Pawel Dyk; D. Mullen; L. Eschen; S. Fergus; R.I. Chin; Wade L. Thorstad; Joseph O. Deasy
PURPOSE Patients with head and neck cancer who undergo radiotherapy often experience several undesirable side-effects, including xerostomia, trismus, and pain in the head and neck area, but little is know about the dose-volume predictors of such pain. We investigated the association between radiation dose and both throat and esophagus pain during radiotherapy. METHODS We analyzed 124 head and neck patients who received radiotherapy at the Washington University School of Medicine in Saint Louis. For these patients, weekly PROs were recorded, including 16 pain and anatomical location questions. In addition, 17 observational symptoms were recorded. Patients were asked to describe their pain at each site according to a four-level scale: none (0), mild (1), moderate (2), and severe (3). We explored the association between throat pain and the mean dose received in oral cavity and between esophageal pain and the mean dose received in the esophagus. The severity of pain was determined by the difference between the baseline (week 1) pain score and the maximum pain score during treatment. The baseline pain score was defined as the first available pain score before receiving 10 Gy because radiotherapy pain originates later during treatment. Dose-volume metrics were extracted from treatment plans using CERR. To evaluate the correlation between pain and radiation dose, Spearmans correlation coefficient (Rs) was used. RESULTS The associations between throat pain and the mean dose to the oral cavity, and between esophagus pain and the mean dose to the esophagus, were both statistically significant, with Rs=0.320 (p=0.003) and Rs=0.424 (p<0.0001), respectively. Mean dose, for each structure, was a better predictor of pain than total integral dose. CONCLUSION We demonstrated that pain during radiotherapy in head and neck patients highly correlates with the dose delivered. We will further investigate the association between other pain locations and relevant normal tissue dose characteristics.
World Journal of Urology | 2015
Vivek Verma; Ling Chen; Jeff M. Michalski; Yanle Hu; Wenjun Zhang; Kathryn Robinson; Shivam Verma; L. Eschen; S. Fergus; Dan Mullen; Seth A. Strope; Robert L. Grubb
International Journal of Radiation Oncology Biology Physics | 2011
Pawel Dyk; Joseph O. Deasy; D. Mullen; L. Eschen; H. Pope; Todd DeWees; Wade L. Thorstad
International Journal of Radiation Oncology Biology Physics | 2016
Joseph O. Deasy; A. Apte; Mackenzie Daly; Douglas Adkins; Jason T. Rich; Loren Michel; Tanya M. Wildes; Pawel Dyk; D. Mullen; L. Eschen; R.I. Chin; Brian Nussenbaum; Bruce H. Haughey; Wade L. Thorstad; Jung Hun Oh
International Journal of Radiation Oncology Biology Physics | 2013
V. Verma; Ling Chen; J.M. Michalski; Yanle Hu; W. Zhang; L. Eschen; S. Fergus; D. Mullen; Seth A. Strope
International Journal of Radiation Oncology Biology Physics | 2013
Stephanie Markovina; A. McCandless; Shahed N. Badiyan; D. Mullen; L. Eschen; Todd DeWees; J.M. Michalski
International Journal of Radiation Oncology Biology Physics | 2012
A. Molotievschi; Todd DeWees; L. Eschen; D. Mullen; J. Clohisy; J. Brandon; Jeffrey D. Bradley; C.G. Robinson
International Journal of Radiation Oncology Biology Physics | 2011
Pawel Dyk; J.O. Deasey; Wade L. Thorstad; Todd DeWees; D. Mullen; L. Eschen